Attached files
file | filename |
---|---|
EX-31.2 - EX-31.2 - AKCEA THERAPEUTICS, INC. | akca-ex312_9.htm |
EX-32.1 - EX-32.1 - AKCEA THERAPEUTICS, INC. | akca-ex321_10.htm |
10-K - 10-K - AKCEA THERAPEUTICS, INC. | akca-10k_20191231.htm |
EX-31.1 - EX-31.1 - AKCEA THERAPEUTICS, INC. | akca-ex311_8.htm |
EX-10.4 - EX-10.4 - AKCEA THERAPEUTICS, INC. | akca-ex104_278.htm |
EX-21.1 - EX-21.1 - AKCEA THERAPEUTICS, INC. | akca-ex211_7.htm |
EX-4.5 - EX-4.5 - AKCEA THERAPEUTICS, INC. | akca-ex45_490.htm |
EX-10.15 - EX-10.15 - AKCEA THERAPEUTICS, INC. | akca-ex1015_357.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
(2) |
Registration Statement (Form S-8 No. 333-231613) pertaining to the 2017 Employee Stock Purchase Plan of Akcea Therapeutics, Inc., |
|
(3) |
Registration Statement (Form S-8 No. 333-228969) pertaining to the 2015 Equity Incentive Plan of Akcea Therapeutics, Inc., |
|
(4) |
Registration Statement (Form S-8 No. 333-225730) pertaining to the 2015 Equity Incentive Plan and 2017 Employee Stock Purchase Plan of Akcea Therapeutics, Inc., and |
|
(5) |
Registration Statement (Form S-8 No. 333-219290) pertaining to the 2015 Equity Incentive Plan and 2017 Employee Stock Purchase Plan of Akcea Therapeutics, Inc; |
of our report dated March 2, 2020, with respect to the consolidated financial statements of Akcea Therapeutics, Inc., included in this Annual Report (Form 10-K) of Akcea Therapeutics, Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
San Diego, California
March 2, 2020